BioPlus Acquisition Corp. Warrants
BIOSW
BIOSW was delisted on the 6th of October, 2023.
49 hedge funds and large institutions have $2.99M invested in BioPlus Acquisition Corp. Warrants in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
4% less funds holding
Funds holding: 51 → 49 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
42% less capital invested
Capital invested by funds: $5.12M → $2.99M (-$2.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$68.1K |
| 2 |
ACM
Atalaya Capital Management
New York
|
+$13.9K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$9.73K |
| 4 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
+$8.36K |
| 5 |
CS
Clear Street
New York
|
+$3.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.01M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
-$14K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$8K |
| 4 |
CC
Centiva Capital
New York
|
-$7K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.1K |
BIOSW Hedge Fund Activity: Q3 2022 in Review
49 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Warrants (BIOSW) for Q3 2022, worth a combined $2.99M — down 42% from $5.12M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BIOSW and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Periscope Capital, adding an estimated $68.1K. The largest seller was Mangrove Partners, exiting entirely with an estimated $2.01M sold.
- 49 institutional investors held BioPlus Acquisition Corp. Warrants (BIOSW) as of Q3 2022, down from 51 in Q2 2022.
- Funds reported $2.99M of BioPlus Acquisition Corp. Warrants stock for Q3 2022, down 42% quarter-over-quarter.
- 3 funds opened new BioPlus Acquisition Corp. Warrants positions in Q3 2022 and 5 closed out, a net change of -2 holders.
- The largest BioPlus Acquisition Corp. Warrants buyer in Q3 2022 was Periscope Capital, an estimated $68.1K added.
- The largest BioPlus Acquisition Corp. Warrants seller in Q3 2022 was Mangrove Partners, an estimated $2.01M sold.
Based on aggregated 13F filings for Q3 2022.